Thursday, December 29, 2022

Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogen

The report said the F.D.A.’s approval process for Aduhelm was “rife with irregularities” and criticized Biogen for setting an “unjustifiably high price.”

from NYT > Top Stories https://ift.tt/jYOPTCi
at
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

A Wildlife Regulator’s Family Business Had a Permit to Renew. She Stepped In.

Jenifer Chatfield, a top official at the Interior Department, faces scrutiny from ethics experts for actions that could help her family’s bu...